Loading...
XSWX
SFZN
Market cap4.35bUSD
Apr 04, Last price  
855.00CHF
1D
-3.39%
1Q
-13.90%
Jan 2017
301.41%
Name

Siegfried Holding AG

Chart & Performance

D1W1MN
P/E
23.38
P/S
2.89
EPS
36.57
Div Yield, %
0.42%
Shrs. gr., 5y
0.46%
Rev. gr., 5y
9.21%
Revenues
1.29b
+1.82%
318,335,000299,766,000318,256,000288,745,000283,041,000314,409,000328,095,000367,800,000374,940,000315,282,000480,571,000717,729,000750,468,000794,297,000833,514,000845,062,0001,102,423,0001,229,518,0001,271,494,0001,294,573,000
Net income
160m
+41.93%
36,534,00032,392,00049,710,000-74,834,000-35,263,000-16,243,0009,599,00020,868,00053,851,00038,556,00039,100,00027,906,00039,732,00056,310,00053,147,00060,867,00095,600,000156,490,000112,774,000160,064,000
CFO
169m
-19.09%
47,953,00052,142,00062,657,00022,294,00045,465,00057,677,00031,810,00054,322,00067,529,00024,642,00023,075,00057,113,00084,632,000106,001,00055,858,000105,284,000112,357,000134,505,000208,608,000168,777,000
Dividend
May 03, 20243.6 CHF/sh
Earnings
Apr 18, 2025

Profile

Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling injectables, ophthalmics, and inhalative products. It offers contract development and manufacturing services, including pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale up and clinical trial material production. In addition, the company provides APIs and controlled substances focusing on anesthetics, pain treatment applications, and central nervous and respiratory diseases. Further, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
URL
https://www.siegfried.ch/
IPO date
Jan 01, 1973
Employees
3,633
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,294,573
1.82%
1,271,494
3.41%
1,229,518
11.53%
Cost of revenue
1,104,992
1,104,412
997,165
Unusual Expense (Income)
NOPBT
189,581
167,082
232,353
NOPBT Margin
14.64%
13.14%
18.90%
Operating Taxes
36,379
37,682
62,284
Tax Rate
19.19%
22.55%
26.81%
NOPAT
153,202
129,400
170,069
Net income
160,064
41.93%
112,774
-27.94%
156,490
63.69%
Dividends
(15,386)
(14,438)
(13,535)
Dividend yield
0.36%
0.39%
0.51%
Proceeds from repurchase of equity
(17,779)
(5,467)
(23,008)
BB yield
0.42%
0.15%
0.87%
Debt
Debt current
55,541
Long-term debt
445,000
590,000
Deferred revenue
(1)
Other long-term liabilities
628,780
159,735
162,099
Net debt
(39,339)
388,060
553,332
Cash flow
Cash from operating activities
168,777
208,608
134,505
CAPEX
(165,301)
(127,441)
(115,208)
Cash from investing activities
(190,346)
(146,864)
(103,715)
Cash from financing activities
3,039
(94,750)
(10,683)
FCF
(1,875)
84,233
90,552
Balance
Cash
39,612
56,626
91,618
Long term investments
(273)
314
591
Excess cash
30,733
Stockholders' equity
886,276
731,622
813,040
Invested Capital
1,608,688
1,442,868
1,432,294
ROIC
10.04%
9.00%
12.14%
ROCE
11.65%
11.42%
15.75%
EV
Common stock shares outstanding
4,341
4,300
4,313
Price
986.00
14.72%
859.50
40.10%
613.50
-31.03%
Market cap
4,279,845
15.79%
3,696,117
39.67%
2,646,281
-31.45%
EV
4,240,222
4,084,074
3,199,613
EBITDA
274,307
248,435
314,301
EV/EBITDA
15.46
16.44
10.18
Interest
8,500
9,300
7,574
Interest/NOPBT
4.48%
5.57%
3.26%